Dyne Therapeutics, Inc.
(NASDAQ : DYN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.75%428.530.0%$5865.30m
BNTXBioNTech SE -4.54%355.720.0%$1225.60m
NVAXNovavax, Inc. -1.73%233.1779.4%$923.11m
SNSSSunesis Pharmaceuticals, Inc. 0.12%8.530.7%$596.28m
AMGNAmgen, Inc. 0.12%217.631.4%$528.58m
REGNRegeneron Pharmaceuticals, Inc. -1.10%645.992.7%$517.02m
GILDGilead Sciences, Inc. -0.62%70.891.0%$419.03m
ILMNIllumina, Inc. -0.55%447.473.5%$378.04m
TECHBio-Techne Corp. 0.93%534.374.5%$331.36m
BIIBBiogen, Inc. -0.46%298.311.7%$291.44m
VRTXVertex Pharmaceuticals, Inc. -0.14%186.841.9%$230.24m
ISEEIVERIC bio, Inc. -1.91%16.050.0%$185.54m
BGNEBeiGene Ltd. 4.09%401.011.3%$165.92m
LIFEaTyr Pharma, Inc. -6.43%9.603.2%$130.36m
KDMNKadmon Holdings, Inc. -0.68%8.760.9%$127.22m

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.